Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma

Annals of Oncology

Volumn 7, Issue 2, 1996, Pages 173-178

  Andre T ^a   Lotz, J P ^a   Bouleuc, C ^a   Azzouzi, K ^a   Houry, S ^a   Hannoun, L ^b   See, J ^a   Esteso, A ^a   Avenin, D ^a   Izrael, V ^a  

^a HÔPITAL TENON   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

5 fluorouracil; Advanced pancreatic adenocarcinoma; Cisplatin; Leucovorin

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; DIARRHEA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROPATHY; NEUTROPENIA; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

EID: 13344286320     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010545     Document Type: Article

References (28)

1. Brennan MF, Kinsella TJ, Casper ES. Cancer of the pancreas. In DeVita VT, Hellman S, Rosenberg SA (eds.): Cancer: Principles and Practice of Oncology, 4th ed. Philadelphia: JB Lippincott 1993;849-82.
2. Warshaw AL, Ferńandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992; 326: 455-65.
3. Gudjonsson B. Cancer of the pancreas: 50 years of surgery. Cancer 1987; 60: 2284-303.
4. Carter SK. The integration of chemotherapy into a combined modality approach for cancer treatment: VI. Pancreatic adenocarcinoma. Cancer Treat Rev 1975; 3: 193.
5. Frey C, Twomey P, Keehn R et al. Randomized study of 5-FU and CCNU in pancreatic cancer Report of the Veterans' Administration Surgical Adjuvant Cancer Chemotherapy Study Group. Cancer 1981; 47: 27-31.
6. Anderson JR, Friis-Mollek A, Hancke S et al. A controlled trial of combination chemotherapy with 5-FU and BCNU in pancreatic cancer. Scand J Gastroenterol 1981; 16: 973.
7. Mallinson CN, Rake MO, Cocking JB et al. Chemotherapy in pancreatic cancer: Results of a controlled, prospective, randomized, multicenter trial. BMJ 1980; 281: 1589-91.
8. Palmer KR, Kerr M, Knowles G et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994; 8: 882-5.
9. Mini E, Trave F, Rustum YM et al. Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. Pharmacol Ther 1990; 47: 1-19.
10. The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
11. Trave F, Rustum YM, Goranson J. Synergistic antitumor activity of cisplatin (DDP) and 5-fluorouracil in mice bearing leukemia L1210 cells. Proc Am Assoc Cancer Res 1985; 26: 322 (Abstr).
12. Arbuck SG, Douglass HO Jr, Nava HR et al. Progress report on studies of FAM-CF for gastric cancer and intraperitoneal administration of 5-FU/CF followed by cisplatin. In McGuire J, Rustum YM (eds): The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy. New York: Plenum 1988; 285-93.
13. Vokes EE, Schilsky RL. Weichselbaum RR et al. Cisplatin, 5-fluorouracil and high-dose oral leucovorin for advanced head and neck cancer. Cancer 1989; 63: 1048-53.
14. Crown J, Casper ES, Botet J et al. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991; 9: 1682-6.
15. Weinerman BH, McCormick RE. A phase II survival comparison of patients with adenocarcinoma of the pancreas treated with 5-fluorouracil and calcium leucovorin versus a matched tumor registry control population. Am J Clin Oncol 1994; 17: 467-9.
16. Bruckner HW, Crown J, McKenna A et al. Leucovorin and 5-fluorouracil as a treatment for disseminated cancer of the pancreas and unknown primary tumors. Cancer Res 1988; 48: 5570-2.
17. DeCaprio JA, Arbuck SG, Mayer RJ. Phase II study of weekly 5-fluorouracil (5-FU) and folinic acid (FA) in previously untreated patients with unresectable measurable pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 1989; 8: 100 (Abstr).
18. Kantarjian H, Ajani JA, Karlian DA. Cis-diaminedichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract. Oncology 1985; 42: 69-71.
19. Wils JA, Kok T, Wagener DJ et al. Activity of cisplatin in adenocarcinoma of the pancreas. Eur J Cancer 1993; 29A: 203-4.
20. Cullinan S, Moertel CG, Wieand HS et al. A phase III trial on the therapy of advanced pancreatic carcinoma: Evaluations of the Mallinson regimen and combined 5-fluorouracil. doxorubicin, and cisplatin. Cancer 1990; 65: 2207-12.
21. Moertel CG, Rubin J, O'Connell MJ et al. A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas. J Clin Oncol 1986; 4: 1053-7.
22. Kelsen D, Hudis C, Niedzwiecki D et al. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer 1991; 68: 965-9.
23. Dougherty JB, Kelsen D, Kemeny N et al. Advanced panreatic cancer: A phase I-II trial of cisplatin, high-dose cytarabine, and caffeine. J Natl Cancer Inst 1989; 81: 1735-8.
24. Rougier P, Zarba JJ, Ducreux M et al. Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann Oncol 1993; 4: 333-6.
25. Rothman H, Cantrell JE, Lokich J et al. Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma: A Mid-Atlantic Oncology Program study. Cancer 1991; 68: 264-8.
26. Gattani A, Mandeli J, Chesser MR et al. An active biochemical modulation regimen for advanced adenocarcinoma of the pancreas. Proc Am Assoc Clin Oncol 1992; 11: 193 (Abstr).
27. Nicolson M, Webb A, Cunningham, et al. Cisplatin and protracted venous infusion 5-fluorouracil (CF) - good symptom relief with low toxicity in advanced pancreatic carcinoma. Ann Oncol 1995; 8: 801-4.
28. Poon MA, O'Connel MJ, Wienand HS et al. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer J Clin Oncol 1991; 9: 1967-72.